MRNA Latest Press Releases

-- October 26, 2026 --

Immuno-Oncology Emerges as a Major Force in the Global Cancer Treatment Market Globe Newswire 9:00 AM

A Personalized Cancer Therapy Delivered Positive Phase 3 Results; The Next Race Is Picking Better Targets Globe Newswire 8:53 AM

-- October 23, 2026 --

Lost Money on Moderna, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 23.07% Share Price Drop Business Wire 11:00 AM

Did You Lose Money on Moderna, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 23.07% Share Price Decline Business Wire 9:00 AM

Moderna Named a Top Employer by Science for Twelfth Consecutive Year ACCESS Newswire 7:00 AM

-- October 22, 2026 --

Lost Money on Moderna, Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 23.07% Stock Decline Business Wire 3:14 PM

Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA (pembrolizumab) at ESMO 2026 Presidential Symposium Business Wire 2:59 PM

-- October 14, 2026 --

AI-Designed Biologics Are Moving From the Screen to the Bench, and Developers Are Hiring for the Next Test Globe Newswire 9:45 AM

-- October 13, 2026 --

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026 ACCESS Newswire 7:00 AM

-- October 7, 2026 --

2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope Globe Newswire 9:59 AM

-- October 1, 2026 --

Moderna, Inc. to Join the Nasdaq-100 Index Beginning October 9, 2026 Globe Newswire 8:00 PM

-- September 30, 2026 --

Moderna Adds Chief Operating Officer Role as Company Expands into Oncology ACCESS Newswire 7:00 AM

-- September 21, 2026 --

Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026 ACCESS Newswire 10:12 AM

-- September 15, 2026 --

A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat Globe Newswire 9:00 AM

-- September 1, 2026 --

Moderna to Present at Upcoming Conferences in September 2026 ACCESS Newswire 7:00 AM

-- August 28, 2026 --

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes ACCESS Newswire 7:00 AM

-- August 27, 2026 --

Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines ACCESS Newswire 3:57 PM

Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes ACCESS Newswire 7:20 AM

-- August 26, 2026 --

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer's Biggest Opportunity Globe Newswire 9:20 AM

-- August 19, 2026 --

Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma Business Wire 6:45 AM

-- August 5, 2026 --

Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA ACCESS Newswire 10:15 PM

-- August 4, 2026 --

Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus ACCESS Newswire 11:00 AM

-- July 31, 2026 --

Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates ACCESS Newswire 7:00 AM

-- July 16, 2026 --

Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors ACCESS Newswire 7:00 AM

-- July 9, 2026 --

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026 ACCESS Newswire 7:00 AM

-- July 8, 2026 --

Moderna Appoints Michael McDonnell to Board of Directors ACCESS Newswire 7:00 AM

-- June 25, 2026 --

Moderna Science Day Highlights Expanding Potential of mRNA Platform ACCESS Newswire 7:00 AM

-- June 18, 2026 --

Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine ACCESS Newswire 4:00 PM

-- June 17, 2026 --

Moderna to Host Investor Event - Science Day ACCESS Newswire 7:00 AM

-- June 16, 2026 --

Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028 ACCESS Newswire 7:30 AM

-- June 8, 2026 --

Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome ACCESS Newswire 7:01 PM

-- June 3, 2026 --

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion Globe Newswire 8:30 AM

-- June 2, 2026 --

Moderna to Present at Upcoming Conference in June 2026 ACCESS Newswire 7:00 AM

-- June 1, 2026 --

Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting ACCESS Newswire 8:00 AM

Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus ACCESS Newswire 5:00 AM